Lumipulse® G Total Tau
Immunoreaction cartridge for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of total Tau in human cerebrospinal fluid (CSF).
This CSF biomarker is intended to be used as an aid for diagnosis in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.
Product number 230312
Product number 230329
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Other documents
FileFileWhitepaper - Biomarkers for Alzheimers disease.pdf (pdf, 148.72 kb)FileFileFilePractical guide for lumbar puncture.pdf (pdf, 263.94 kb)Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Webinars: Current topics in Alzheimer's disease diagnostics
Over the coming months we are hosting a webinar series with leading expert speakers and dedicated to current topics in the field of Alzheimer's...
Sep 21, 2021
Early diagnosis of Alzheimer's disease is crucial. The desire to tackle neurodegenerative diseases by always finding earlier diagnostic solutions and...
Sep 21, 2021
This 2 minute video explains why and how a ratio calculation of the two amyloid proteins, Aβ1-42 and Aβ1-40, offers particularly essential information...
Sep 20, 2021
-
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Related products
-
Product inquiry
